Left-DLPFC rTMS Shows Dual Symptom Relief in Depression With Insomnia
High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) aimed at the left dorsolateral prefrontal cortex appears to improve both sleep and mood in patients living with depression and insomnia symptoms, based on a systematic review and meta-analysis of randomized controlled trials. Across 7 studies and 709 participants, the treatment signal ran in the same direction for both primary symptom domains: sleep quality improved, and depressive symptoms fell.
The pooled estimate for sleep quality was sizable. Investigators reported a standardized mean difference of 0.97, with a 95% confidence interval from 0.23 to 1.71 and a p value of 0.01. Depressive symptoms improved as well, with a standardized mean difference of 0.61, a 95% confidence interval of 0.38 to 0.84, and a p value below 0.00001. In practical terms, the intervention did not just move mood scales; it also tracked with better nocturnal functioning in a population where insomnia and depression often reinforce one another.
Sleep latency did not separate cleanly between groups. The pooled estimate suggested a trend toward shorter time to fall asleep, but the result did not reach statistical significance, with a standardized mean difference of 0.50 and a 95% confidence interval from −0.17 to 1.18. Safety looked reassuring in the pooled analysis, with no significant difference in adverse reactions between groups and a risk ratio of 1.09, 95% confidence interval 0.80 to 1.48. The intervention was not associated with an obvious tolerability penalty in the available trials.
Why the Left DLPFC Matters for a Sleep-Mood Syndrome
Depression and insomnia rarely sit apart in the same patient. They often travel together through shared neurobiology that includes hypothalamic-pituitary-adrenal axis dysregulation, monoaminergic disturbance, circadian disruption, and reduced prefrontal cortex excitability. The left dorsolateral prefrontal cortex is a plausible therapeutic target because it sits within circuits governing affect regulation, executive control, and arousal balance. Stimulating this region at high frequency is intended to enhance cortical excitability, which may help restore function in networks that are underactive in depressive illness.
That logic matters at the bedside because insomnia in depression is not simply a symptom to be counted after the mood outcome is resolved. It can worsen daytime impairment, complicate recovery, and increase the chance that antidepressant treatment will feel incomplete even when mood improves. A therapy that can affect both dimensions at once has obvious appeal, especially when pharmacologic options are limited by adverse effects, withdrawal concerns, nonresponse, or relapse.
The review focused on a narrower question than many earlier analyses. Instead of treating insomnia as a secondary byproduct of mood improvement, it asked whether left DLPFC-targeted HF-rTMS can improve sleep-related outcomes in patients with comorbid depression and insomnia symptoms. That distinction is important because studies in primary insomnia have used different stimulation targets and frequency schemes, making them hard to extrapolate to a psychiatric comorbidity population.
Heterogeneity Pointed to Stimulation Frequency and Antidepressant Use
The signal for sleep quality did not come from a uniform dataset. Heterogeneity was substantial for Pittsburgh Sleep Quality Index outcomes, with an I² of 91%. Such variability weakens confidence in a single pooled point estimate and suggests that study design differences were shaping the results. Subgroup analyses pointed to two drivers: stimulation frequency and baseline antidepressant use.
Those findings fit clinical intuition. Different frequencies can alter cortical excitability in distinct ways, and background antidepressant therapy may change the apparent effect size by either amplifying or obscuring the contribution of neuromodulation. In a disorder defined by overlapping symptom pathways, even small protocol differences can ripple through the final outcome. The meta-analysis did not resolve the ideal dose, pulse count, or patient profile, but it did show that not all rTMS protocols are interchangeable.
One sentence captures the central tension in the data: the therapy looks promising, yet the treatment effect was not stable enough across studies to support a simple one-size-fits-all conclusion.
What the Numbers Support and What They Do Not
The review’s overall interpretation was cautious. The evidence base supports a possible benefit for both sleep quality and depressive symptoms, but the certainty of evidence was rated very low to low. Methodological limitations and heterogeneity prevented a stronger claim. The authors also did not establish whether sleep improvement occurred independently of antidepressant benefit or merely reflected mood improvement spilling over into better nighttime rest.
That unresolved mechanism matters clinically. If sleep benefits arise only when mood improves, then treatment planning may differ from a scenario in which HF-rTMS directly targets insomnia circuitry. The answer affects target selection, trial design, and how clinicians counsel patients about expectations. It also shapes whether future studies should measure sleep as a co-primary endpoint rather than as a downstream secondary outcome.
The tolerability data were encouraging but still limited. No clear excess of adverse reactions emerged in the pooled analysis, which supports the idea that left DLPFC HF-rTMS can be delivered without an obvious short-term safety penalty in this population. Even so, pooled safety findings from seven studies cannot settle questions about less common adverse events, longer treatment courses, or durability after the stimulation phase ends.
A Signal Worth Testing in Larger Trials
The current evidence points toward a treatment strategy that may help two difficult symptoms at once: low mood and disturbed sleep. Patients with depression and insomnia often cycle between fragmented sleep, fatigue, impaired concentration, and reduced emotional resilience, making incremental improvement meaningful even when remission is not yet in reach. A nonpharmacologic approach that avoids medication burden may be especially valuable for patients who cannot tolerate standard drugs or who have not responded adequately to them.
Still, the data remain exploratory. Seven studies and 709 participants are enough to generate a clinically interesting signal, not enough to define practice on their own. Future trials will need tighter protocol standardization, clearer reporting of stimulation parameters, and better separation of sleep outcomes from mood outcomes. They will also need to determine whether the apparent benefit is durable, whether it varies by baseline antidepressant exposure, and whether certain frequency settings consistently outperform others.
For now, the evidence places left DLPFC-targeted HF-rTMS in the category of a plausible adjunctive option rather than a settled standard. The appeal is real, but the treatment map is still incomplete.